- Home
- RLTY vs TARA Comparison
RLTY vs TARA Comparison
Compare RLTY & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLTY | TARA |
|---|---|---|
| Founded | 2022 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.2M | 269.8M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RLTY | TARA |
|---|---|---|
| Price | $15.52 | $4.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.40 |
| AVG Volume (30 Days) | 45.6K | ★ 777.9K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 9.35% | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.04 | $2.77 |
| 52 Week High | $15.97 | $7.82 |
Technical Indicators
Market Signals| Indicator | RLTY | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 40.08 |
| Support Level | $15.30 | $3.62 |
| Resistance Level | $15.89 | $5.53 |
| Average True Range (ATR) | 0.26 | 0.24 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 11.86 | 34.60 |
Price Performance
Historical ComparisonAbout RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income. Its secondary investment objective is capital appreciation. The fund invests the majority of its managed assets in real estate-related investments and preferred and other income securities.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.